
• Reported GAAP EPS of -$0.39 up 70.68% YoY • Reported revenue of $17.54M • Verastem expects a cash runway into the first half of 2027, fueled by existing cash and product revenue. The company aims to accelerate VS-7375 clinical development and report RAMP 301 trial topline data in mid-2027.
Bullish
Verastem achieved $30.9 million in full year 2025 product revenue from AVMAPKI FAKZYNJA CO-PACK after accelerated FDA approval. Its VS-7375 pipeline showed encouraging safety, and GFH375 received Breakthrough Therapy Designation in China.
Bearish
Verastem faces NCCN guideline limitations for its key product, increased operating expenses due to R&D and commercialization, and a higher GAAP net loss of $209.5 million for the full year 2025.